Lilly’s Oral GLP-1 Bests Another Big Pharma Bestseller in Phase III Diabetes Trial

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.